NKTR

NEKTAR THERAPEUTICS

NKTR·640268306·US·Common Stock·Healthcare - Biotechnology-13D/G

NKTR (NEKTAR THERAPEUTICS) is held by 103 institutional investors as of Q1 2026. Largest holders: FMR LLC ($309.6M), VANGUARD CAPITAL MANAGEMENT LLC ($86.1M), TWO SIGMA INVESTMENTS, LP ($67M). Net institutional sentiment: Bullish.

103
Holders
Avg rating(15 Elite)
$1.1B
Total Value
72% (112)
Fund Consensus
75 buying - 29 selling
NKTRSmart Money Verdict
View all
Held by 103 funds
15 elite
Who's Trading
ActivistBLBVF PARTNERS L P/IL9.8%May 15, 2026
ActivistFMR LLCFMR LLC15.0%May 6, 2026
ActivistTSTwo Seas Capital LP6.8%Apr 17, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderRWROBIN HOWARD WSell $31KFeb 18, 2026
InsiderZJZalevsky JonathanSell $13KFeb 18, 2026
ActivistGEG1 Execution Services, LLC4.0%Feb 13, 2026
InsiderZJZalevsky JonathanSell $138KJan 20, 2026
InsiderRWROBIN HOWARD WSell $120KNov 25, 2025
InsiderWAWilson Mark AndrewSell $34KNov 25, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
4.3M(+4155.1%)$309.6M0.0%+4.25%
50
New
1.2M$86.1M0.0%+3.30%
41
Increased
930,741(+96.8%)$67M0.1%+17.64%
47
Increased
692,650(+7.3%)$49.8M0.0%+121.40%
31
Increased
659,387(+16.4%)$47.4M0.0%+22.35%
34
Increased
567,458(+21.2%)$40.8M0.0%+22.71%
35
Increased
513,531(+65.8%)$36.9M0.0%+12.46%
43
Increased
415,335(+299.4%)$29.9M0.1%+28.11%
56
Decreased
404,277(-11.0%)$29.1M0.0%+396.24%
0
Increased
390,675(+20.6%)$28.1M0.0%+51.14%
34
Increased
346,795(+36.3%)$25M0.0%-28.16%
37
Increased
320,172(+11.3%)$23M0.0%+90.09%
32
Decreased
279,150(-0.4%)$20.1M0.0%-85.65%
0
Increased
271,758(+30.5%)$19.6M0.2%+24.85%
43
Decreased
249,090(-35.0%)$17.9M0.0%+47.95%
0
Increased
244,727(+25.1%)$17.6M0.0%+48.38%
35
Increased
240,102(+59.2%)$15.7M0.0%+36.24%
40
New
169,308$12.2M0.0%+3.30%
39
Increased
168,007(+39.6%)$12.1M0.0%-38.83%
37
Increased
140,588(+485.2%)$10.1M0.0%+10.57%
45

Showing 1-20 of 112

1 / 6

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used